NCT00781612 2025-12-24A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesGenentech, Inc.Phase 2 Active not recruiting720 enrolled